MK-5108 (VX-689) is a highly selective Aurora-A kinase inhibitor with an IC50 of 0.064 nM. MK5108 (VX689) inhibited growth of human tumor cell lines in culture and in different xenograft models. Furthermore, the combination of MK 5108 and docetaxel showed enhanced antitumor activities compared with control and docetaxel alone-treated animals without exacerbating the adverse effects of docetaxel. [1][2]